Van Ness BG - Search Results

1

secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics.

Kumar H, Mazumder S, Chakravarti S, Sharma N, Mukherjee UK, Kumar S, Baughn LB, Van Ness BG, Mitra AK. Kumar H, et al. Among authors: van ness bg. Blood Cancer J. 2022 Mar 9;12(3):39. doi: 10.1038/s41408-022-00636-2. Blood Cancer J. 2022. PMID: 35264575 Free PMC article.

2

Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients.

Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B. Billadeau D, et al. Blood. 1992 Oct 1;80(7):1818-24. Blood. 1992. PMID: 1391945 Free article.

3

Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease.

Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Billadeau D, et al. Blood. 1991 Dec 1;78(11):3021-9. Blood. 1991. PMID: 1954387 Free article.

4

Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma.

Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, Witzig TE. Billadeau D, et al. Blood. 1996 Jul 1;88(1):289-96. Blood. 1996. PMID: 8704185 Free article.

5

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.

Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B. Liu P, et al. Blood. 1996 Oct 1;88(7):2699-706. Blood. 1996. PMID: 8839865 Free article. Clinical Trial.

6

Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.

Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Billadeau D, et al. Cancer Res. 1997 Jun 1;57(11):2268-75. Cancer Res. 1997. PMID: 9187131

7

Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.

Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. Greipp PR, et al. Blood. 1998 Apr 1;91(7):2501-7. Blood. 1998. PMID: 9516151 Free article. Clinical Trial.

8

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.

Oken MM, Leong T, Lenhard RE Jr, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA. Oken MM, et al. Cancer. 1999 Sep 15;86(6):957-68. Cancer. 1999. PMID: 10491521 Clinical Trial.

9

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

Rowley M, Liu P, Van Ness B. Rowley M, et al. Blood. 2000 Nov 1;96(9):3175-80. Blood. 2000. PMID: 11050000 Free article.

10

Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients.

Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B, Oken MM, Kyle RA. Kay NE, et al. Blood. 2001 Jul 1;98(1):23-8. doi: 10.1182/blood.v98.1.23. Blood. 2001. PMID: 11418458 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters